Jane Street’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Jane Street’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-24,089	Closed	-$2.59M	–	9930
2023 Q1	$2.59M	Buy	24,089 +16,680	+225%	+$1.92M	﹤0.01%	3395
2022 Q4	$815K	Buy	+7,409	New	+$480K	﹤0.01%	5307
2022 Q3	–	Sell	-10,416	Closed	-$477K	–	10775
2022 Q2	$294K	Buy	+10,416	New	+$302K	﹤0.01%	7646

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Jane Street's RXDX Position: Q2 2023 in Review

Jane Street sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 24,089 shares — an estimated $2.59M sold.

Jane Street first reported a position in RXDX in Q2 2022 and held it in 3 quarters. The position peaked at $2.59M in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Jane Street reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Jane Street sold 24,089 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $2.59M.
Jane Street first reported a position in Prometheus Biosciences, Inc. Common Stock in Q2 2022 and held it in 3 quarters.
Jane Street's Prometheus Biosciences, Inc. Common Stock position peaked at $2.59M in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Jane Street's 13F filing for Q2 2023, filed 14 Aug 2023.